MorphoSys has received a clinical milestone payment from Bayer, relating to the launch of a Phase II clinical trial on a candidate treatment for rare cancer mesothelioma. The candidate, anetumab ravtansine (BAY 94-9343), was developed by Bayer using the MorphoSys Human Combinatorial Antibody Library (HuCAL) technology, which involves the in-vitro generation of distinct fully human antibodies. Anetumab ravtansine was the fourth antibody developed using the HuCAL technology platform to move into decisive phases of clinical development.
Market Closed -
Other stock markets
|
Pre-market 01:32:00 am | |||
67.75 EUR | 0.00% |
|
67.78 | +0.04% |
Jul. 15 | MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger | MT |
Jul. 12 | Novartis Seeks Squeeze Out Approval at MorphoSys AGM | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+99.26% | 2.78B | |
+25.83% | 47.96B | |
+45.38% | 41.47B | |
+0.69% | 42.45B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- MOR Stock
- News MorphoSys AG
- MorphoSys Earns Milestone Payment as Bayer Launches Phase II Trial of Mesothelioma Candidate